Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 475

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 475
---
, business
development, and organizational planning. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France)
where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine).
Some of Dr. Angel’s previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa,
Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot,
Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’
Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancer. He received a B.Sc. degree from Tel-Aviv University
in 1979 and earned his M.Sc degree from Tel-Aviv University in 1980, both in biology. He further studied at the Hamburg University, Germany,
obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda,
Maryland, where he pursued his research in Neurobiology.

57

Board
Composition

Our
business and affairs are managed under the direction of our board of directors, which currently consists of seven members. The number
of directors is determined by our board of directors, subject to the terms of our amended and restated articles of incorporation and
bylaws Our board of directors will continue to consist of seven members, and our directors will be elected for one-year terms.

Family
Relationships

There
are no family relationships among any of our directors and executive officers.

Director
Independence

Our
board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
his or her background, employment, and affiliations, our board of directors has determined that Matthew Pratt Whalen, Dr. Matthew Paul
Del Giudice, Dr. Craig Eagle and Edward MacPherson, do not have any relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and are independent directors under the Nasdaq Listing Rules.

In
making these determinations, our board of directors considered the current and prior relationships that each non-employee director has
with our company and all other facts